event image 23rd annual Advances in Autism Conference

23rd annual Advances in Autism Conference

Sept. 20, 2019, 1:30 p.m. to Sept. 20, 2019, 8:30 p.m.

450 East 29th St, New York, NY 10016

Hosted by sunmola

Description:

About the Advances in Autism Conference We will be hosting the 23rd annual Advances in Autism Conference at a brand new locaiton this year - Apella!  The annual Conference is a one-day event hosted by Seaver Autism Center for Research and Treatment at Mount Sinai. It includes a series of lectures given by accomplished professionals in the field of autism. The purpose of the conference is to discuss accurate recognition, diagnosis and treatment of autism with attendees, such as: practicing psychiatrists, neurologists, psychologists, geneticists, other health care professionals, neuroscientists, educators, family members and social workers. Program Description This year, the Advances in Autism Conference will focus on Drug Discovery and Development in autism and other neurodevelopmental disorders. Drugs are developed to improve quality of life. The drug discovery and development process is exciting and extremely challenging. To ensure safety and effectiveness, bringing a new drug to market for patients takes many years. From determining genetic factors to target for treatment – to completing pre-clinical research and clinical trials - there are a variety of stakeholders who have key roles in this process. The speakers at the Conference will represent biotech, pharma, academia and family foundations – who will explain the many facets of the drug discovery and development process. SPEAKERS: Joseph D. Buxbaum, PhD Director, Seaver Autism Center for Research and Treatment Vice Chair for Research, Seaver Autism Center Professor and Deputy Chair, Department of Psychiatry, Mount Sinai Stormy J. Chamberlain, PhD Associate Professor, Genetics and Genome Sciences at University of Connecticut Health Center Christopher Dudick CEO, Silas Solutions Omar Khwaja, MD, PhD Chief Medical Officer and Head of Research and Development at Voyager Therapeutics Ana Kostic, PhD Director, Drug Discovery and Development, Seaver Autism Center for Research and Treatment Associate Professor, Psychiatry, Mount Sinai Julie LeMoine PhD Candidate in Applied AR for Autism, UCD School of MME, SMARTlab Co-founder, UMass Medical School, Shriver InovaXR Lab Christine McSherry, RN Founder, Jett Foundation William J. Polvino, MD CEO, Bridge Medicines  Bharat Ramani President at Uplift Innovation, Inc Jordi Serrats, PhD Associate Director; Neuroscience Drug Discovery Unit at Takeda Jack Vanden Heuvel, PhD Professor of Molecular Toxicology, Penn State University Chief Scientific Officer, Beautiful BioSolutions and INDIGO Biosciences, Inc. While we will be able to provide verification of attendance, we will not be able to offer formal CME credit.  Please email annualconference@seaverautismcenter.org or contact Sarah Lynch at 212-241-0349 if you have any questions. If you would like to mail your donation, please mail a check to:Seaver Autism Center, One Gustave L. Levy Place, Box 1230, New York, NY 10029-6574 Mount Sinai Health System is a registered 501(c)3 nonprofit and contributions are tax-deductible the extent permitted by law. https://www.eventbrite.com/e/23rd-annual-advances-in-autism-conference-tickets-63063762411

Discussion